Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest update is out from XORTX Therapeutics Inc ( (TSE:XRTX) ).
On January 29, 2025, XORTX Therapeutics Inc. announced its participation in the Microcap Conference in Atlantic City, highlighting the company’s efforts to engage with investors and update them on its new gout program. The presentation, led by CEO Dr. Allen Davidoff, detailed plans to advance the XRx-026 program for gout towards a New Drug Application filing and discussed preparations for clinical trials of the XRx-008 program for ADPKD. This strategic outreach aims to strengthen investor relations and support the company’s path towards FDA marketing approval for its therapies.
More about XORTX Therapeutics Inc
XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company based in Calgary, Alberta, focused on developing innovative therapies for progressive kidney disease and gout. The company has three advanced clinical products in development, targeting issues such as autosomal dominant polycystic kidney disease (ADPKD), allopurinol intolerant gout, and acute kidney injury related to COVID-19, with a pre-clinical program for Type 2 Diabetic Nephropathy.
YTD Price Performance: -16.87%
Average Trading Volume: 3,924
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: C$4.8M
Find detailed analytics on XRTX stock on TipRanks’ Stock Analysis page.
